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SUMMARY
Aberrant acetylation has been strongly linked to tumorigenesis, and the modulation of acetylation through
targeting histone deacetylases (HDACs) is gathering increasing pace as a viable therapeutic strategy. A ge-
nome-wide loss-of-function screen identified HR23B, which shuttles ubiquitinated cargo proteins to the pro-
teasome, as a sensitivity determinant for HDAC inhibitor-induced apoptosis. HR23B also governs tumor cell
sensitivity to drugs that act directly on the proteasome. The level of HR23B influences the response of tumor
cells to HDAC inhibitors, and HR23B is found at high levels in cutaneous T cell lymphoma in situ, a malignancy
that responds favorably to HDAC inhibitor-based therapy. These results suggest that deregulated protea-
some activity contributes to the anticancer activity of HDAC inhibitors.INTRODUCTION
The recognition that aberrant epigenetic control is an important
determinant in attaining the malignant phenotype has stimu-
lated intense efforts to develop mechanism-based drugs that
regulate epigenetic pathways in cancer (Inche and La Thangue,
2006). Reversible histone acetylation represents a key under-
pinning mechanism involved in epigenetic control. One of the
most rapidly progressing areas, from the perspective of anti-
cancer agents, has been seen in the development of small-mol-
ecule inhibitors of histone deacetylase (HDAC) enzymes (Marks
and Jiang, 2005; Bolden et al., 2006). In cell-based assays,
HDAC inhibitors have a striking effect on tumor cell prolifera-
tion, frequently promoting apoptosis (Richon, 2006; Marks
and Breslow, 2007). Consequently, HDAC inhibitors have en-
tered clinical studies. While the clinical picture is quite variable
and the outcome of HDAC inhibitor-based therapy complex, itis significant that, at the current time, certain types of tumors
are known to undergo a favorable response. Hematological
malignancies appear to be particularly sensitive, and in this re-
spect vorinostat (suberoylanilide hydroxamic acid, or SAHA)
has already shown promising clinical effects in late-stage cuta-
neous T cell lymphoma (CTCL; Mann et al., 2007; Khan and La
Thangue, 2008).
However, significant gaps remain in our understanding of how
HDAC inhibitors exert antitumor activity, and the key mecha-
nisms and pathways through which HDAC inhibition blocks tu-
mor cell proliferation have not been well defined. Although de-
regulating chromatin is likely to be involved in tumor cell killing,
a variety of other mechanisms and pathways that contribute to
the cellular effects of HDAC inhibitors have been described
(Richon, 2006; Inche and La Thangue, 2006; Minucci and Pelicci,
2006; Bolden et al., 2006; Xu et al., 2007). Moreover, elucidating
the critical pathways that govern tumor cell killing should assist inSIGNIFICANCE
It is becoming increasingly clear that acetylation, and specifically histone deacetylation, regulates many key pathways that
drive tumorigenesis. Histone deacetylase (HDAC) inhibitors cause tumor cells to enter apoptosis, and there is great interest
in HDAC inhibitor-based therapies as a new type of anticancer agent. However, many details of the pathways through which
HDAC inhibition causes tumor cell death remain to be resolved. Consequently, understanding of the clinical utility of HDAC
inhibitors has been hampered, and there is a pressing need to identify mechanism-related biomarkers. Our study has elu-
cidated an unexpected yet central role for the proteasome and the proteasome-targeting protein HR23B in HDAC inhibitor-
induced apoptosis. HR23B might provide a useful biomarker for identifying tumors that exhibit a favorable response to
HDAC inhibitors.Cancer Cell 15, 57–66, January 6, 2009 ª2009 Elsevier Inc. 57
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HDAC Inhibitors and the Proteasomeclarifying the clinical spectrum of responsive tumors, which for
the most part remains unclear.
It was against this background that we performed a genome-
wide loss-of-function screen to identify genes that govern the
sensitivity of tumor cells to HDAC inhibitors. We reasoned that
genes identified through the screen might provide insights into
the cellular pathways and molecular mechanisms affected by
HDAC inhibition. Our results revealed a functionally important
pathway involving the proteasome, specifically the protea-
some-targeting activity of HR23B, and its potential role in
HDAC inhibitor-induced cell death. The level of HR23B influ-
ences the outcome of HDAC inhibitor treatment, and protea-
some activity is deregulated through a pathway that involves
HR23B in HDAC inhibitor-treated cells. Our study suggests
that aberrant proteasome activity contributes to the anticancer
activity of HDAC inhibitors and provides a rational basis for iden-
tifying patients that gain clinical benefit from HDAC inhibitor-
based therapies.
RESULTS
Loss-of-Function Screen for HDAC Inhibitor
Sensitivity Genes
The loss-of-function screen used a shRNA library targeting the
vast number of human genes involved in cancer, in which each
shRNA induces strong and specific suppression of gene expres-
sion over prolonged periods of time (Berns et al., 2004). We con-
figured the screen to allow the identification of genes that influ-
ence the sensitivity of U2OS cells to HDAC inhibitors. This
rationale was based on the fact that silencing genes required
for HDAC inhibitor-induced apoptosis would allow cells to sur-
vive in the presence of the drug (Figure 1A). Surviving cells could
then be isolated, and the relevant genes could be identified and
thereafter validated in functional assays as determinants of
HDAC inhibitor sensitivity; the output of the screen is described
in Figure S1 available online.
We focused our attention on a shRNA vector targeting HR23B,
which conferred resistance toHDAC inhibitor-induced apoptosis
in U2OS cells. To determine whether expression of the gene tar-
geted by the shRNA sequence was in fact reduced, the level of
the HR23B protein was investigated. The HR23B protein level
was low in cells stably expressing HR23B-specific shRNA
(Figure 1B). The effect of the shRNA sequence derived from sta-
ble expression was compared to that of a siRNA targeting the
same sequence (SP) and to another siRNA (2) derived from a dif-
ferent region of the HR23B RNA; both siRNAs depleted HR23B
(Figure 1C). Lamin siRNA (L) served as an unrelated gene-spe-
cific control siRNA.
In order to validate the role of HR23B in regulating sensitivity to
HDAC inhibition, we assessed the effect of HR23B depletion us-
ing both HR23B siRNAs on HDAC inhibitor-induced apoptosis.
The introduction of either siRNA against HR23B RNA, including
the SP siRNA, reduced the sensitivity of U2OS cells to undergo
apoptosis in response to HDAC inhibitor treatment (Figure 1D).
Furthermore, mouse embryonic fibroblasts (MEFs) derived
from HR23B/ knockout mice (Ng et al., 2002) were less sensi-
tive to HDAC inhibitor-induced apoptosis than their wild-type
(WT) counterparts (Figure 1E). HR23B is one of two human ho-
mologs of Saccharomyces cerevisiae Rad23 (Schauber et al.,
58 Cancer Cell 15, 57–66, January 6, 2009 ª2009 Elsevier Inc.1998; Sugasawa et al., 1997). However, HR23A siRNA did not
affect HDAC inhibitor-induced apoptosis (Figures 1F and 1G),
indicating that HR23A and HR23B take on distinct roles during
HDAC inhibitor-induced apoptosis in this cell system.
Having established that HR23B is functionally important in
regulating sensitivity to HDAC inhibitors, we next assessed
the effect of HDAC inhibition on HR23B. There was an increase
in the level of HR23B in U2OS cells treated with the HDAC inhib-
itor SAHA (Figure 2A), which reflected higher levels of HR23B
immunostaining (Figure 2B). The increased level of HR23B
was seen in a variety of other cell types treated with HDAC in-
hibitors, including A2780 (ovarian), MCF7 (breast), and H460
(lung) tumor cells (Figure S2A). Other HDAC inhibitors, including
PXD101 and valproic acid (VPA) (Carey and La Thangue, 2006),
together with the natural product trichostatin A (TSA), had a sim-
ilar effect on HR23B without any apparent effect on RNA levels
(Figures 2C and 2D). Moreover, HR23B is acetylated, and acet-
ylation occurred in both untreated and treated cells at 48 hr
(Figures 2E and 2F), with a modest increase in acetylation
occurring at 24 hr treatment (Figure S2B). Thus, HR23B is tar-
geted by the acetylation machinery, and HR23B is regulated
through a posttranscriptional mechanism in HDAC inhibitor-
treated cells.
It was, however, important to assess the regulation of HR23B
by other types of agents that kill cancer cells, particularly those
that also induce apoptosis, to exclude the possibility that
HR23B is generally affected by drug-induced apoptosis. In cells
treated under apoptosis-inducing conditions (Figure S2C) with
different anticancer agents, including etoposide, bleomycin,
doxorubicin, and ultraviolet (UV) light, there was little effect on
HR23B levels (Figures 2G and 2H).
Role of HR23B in HDAC Inhibitor-Treated Cells
HR23B participates in nucleotide excision repair (NER; Suga-
sawa et al., 1997). It binds to the xeroderma pigmentosum com-
plementation group C (XPC) protein, which then interacts with
damaged DNA (Sugasawa et al., 1997), and has another impor-
tant function related to a role in targeting ubiquitylated sub-
strates to the proteasome (Schauber et al., 1998; Chen and
Madura, 2002; Hiyama et al., 1999). A ubiquitin-like domain in
the N-terminal region of HR23B interacts with the proteasome,
and two ubiquitin-associated domains located in an internal
and C-terminal region (Chen et al., 2001; Wilkinson et al., 2001;
Chen and Madura, 2002) allow HR23B to shuttle proteins des-
tined for degradation to the proteasome. To gain insight into
the property of HR23B that is relevant for HDAC inhibitor sensi-
tivity, the effect of HDAC inhibition on XP4PA cells was investi-
gated. XP4PA cells carry a defective XPC gene and exhibit low
NER activity, and as a consequence, the importance of HR23B
in NER is reduced in these cells (Li et al., 1993). However,
XP4PA cells were as sensitive to HDAC inhibitor-induced apo-
ptosis as control humanM2C5 fibroblasts andU2OS cells, which
have normal XPC and NER activity (Figures 3A and 3Ba), and
HR23B was similarly induced in XP4PA cells upon treatment
with HDAC inhibitors (Figure 3Bc) when compared to both
U2OS andM2C5 cells (Figures 3Bb and 3Bd). These results sug-
gest that HDAC inhibitors do not induce apoptosis through an
HR23B-dependent pathway that relies on NER activity.
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To test whether HDAC inhibitors influence the interaction be-
tween HR23B and the proteasome, we investigated the associ-
ation between HR23B and the proteasome, with which HR23B
interacts via the ubiquitin-like domain, allowing HR23B to target
cargo proteins to the proteasome (Wilkinson et al., 2001; Chen
and Madura, 2002). There was an increase in the level of
HR23B bound to the proteasome in HDAC inhibitor-treated
cells when the immunoprecipitating antibody was anti-HR23B
(4-fold; Figure 3Ca), and HR23B levels were similarly increased
when the immunoprecipitating antibody recognized the 20S core
a6 subunit (4-fold; Figure 3Cb). The interaction between
HR23B and the S5a 19S proteasome subunit (Fujiwara et al.,
2004) was also observed to increase after HDAC inhibitor treat-
ment (Figure S1D). The association of HR23B with the protea-
some therefore increases in HDAC inhibitor-treated cells.
To test the idea that proteasome activity is aberrant in HDAC
inhibitor-treated cells, we used an HEK293 cell line expressing
an unstable GFP, GFPu, in which GFP is fused to the Ch1 degron
sequence (Gilon et al., 1998; Bence et al., 2001). The Ch1 se-
quence destabilizes GFP by targeting it for degradation via the
ubiquitin-proteasome pathway; thus, the level of GFP provides
an independent measure of proteasome activity (Bence et al.,
2001). As expected, GFPu was stabilized in the presence of the
Figure 1. HDAC Inhibitor shRNA Loss-of-
Function Screen
(A) U2OSEcR cells were infected with the pRetro-
Super shRNA library and then treated with 2 mM
suberoylanilide hydroxamic acid (SAHA) for up to
25 days, conditions in which apoptosis occurred.
Colonies were harvested, and the genes targeted
by the shRNA were identified. (Further details of
the output from the shRNA screen can be found
in Figure S1.)
(B) Validation of HR23B knockdown. The immuno-
blots show the level of HR23B in pRetroSuper
HR23B U2OS cells (pRSHR23B) derived from the
shRNA screen after two (P2) or five (P5) passages.
PCNA was used as a loading control, and the level
of HR23B is shown for comparison in the parental
line (U2OSEcR).
(C) Transient knockdown of HR23B with siRNA.
siRNAs against different regions in HR23B, includ-
ing a siRNA (referred to as SP) representing the se-
quence in the original pRetroSuper HR23B vector
isolated in the screen in (A) and siRNA 2 against an
unrelated sequence in HR23B RNA, were com-
pared for level of HR23B knockdown at 48 hr after
treatment in U2OS cells. Lamin (L) was used as a
siRNA control and PCNA as a loading control;
 indicates untreated cells.
(D) Levels of sub-G1 apoptotic cells determined by
fluorescence-activated cell sorting (FACS) after
treating U2OS cells with either lamin (L) or
HR23B siRNA (2 and SP; as described in [C]) for
48 hr followed by treatment with SAHA (5 mM) for
48 hr. n = 3; error bars = SEM.
(E) Levels of sub-G1 apoptotic cells determined by
FACS after treating either wild-type (WT) or
HR23B/ mouse embryonic fibroblasts (MEFs)
with SAHA (30 mM) for 48 hr, compared to un-
treated cells. The absolute level of sub-G1 cells
was 52% in WT MEFs and 7% in HR23B/
MEFs. n = 4; error bars = SEM. *p < 0.05 by un-
paired Student’s t test.
(F) Fold induction of sub-G1 phase of the cell cycle
as measured by FACS analysis after treatment of
U2OS cells with control (), HR23A, or HR23B
siRNA as indicated for 48 hr, followed by treatment
with 5 mM SAHA for a further 48 hr. The absolute
level of sub-G1 cells for control, HR23A, and
HR23B siRNA treatment was 52%, 70%, and
15%, respectively. n = 4; error bars = SEM.
(G) Immunoblot showing protein levels of HR23A,
HR23B, and PCNA for the experiment described
in (F).
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level of GFPu reflects the ability of the proteasome to degrade
proteins. Upon titration of different HDAC inhibitors (TSA, SAHA,
and PXD101), there was a significant increase in the level of
GFPu protein relative to control treatment (Figure 3E); moreover,
the increase in GFPu levels did not result from altered RNA levels
(Figure 3F).
We next assessed the effect of HDAC inhibitors on protea-
some activity in vitro. Purified proteasomes from untreated cells
were not directly affected by HDAC inhibitors, in contrast to
the effect of bortezomib, which blocked proteasome activity
(Figure 3Ga). However, proteasomes purified from HDAC inhib-
itor-treated cells displayed decreased proteolytic activity
(Figure 3Gb), which is compatible with the results derived from
the GFPu HEK293 cell line (Figure 3E), namely that proteasome
activity is compromised in HDAC inhibitor-treated cells.
To investigate the role of HR23B in the HDAC inhibitor-depen-
dent effects on proteasome activity, we introduced HR23B
siRNA into the GFP-u1 HEK293 cell line and monitored the ef-
fects on GFPu levels. The increased levels of GFPu observed in
HDAC inhibitor-treated cells were reduced upon the depletion
of HR23B (Figure 3H). These results suggest therefore that
Figure 2. HR23B Regulates Sensitivity
to HDAC Inhibitors
(A) HR23B protein levels in SAHA-treated cells.
Immunoblots show HR23B in U2OS cells after
treatment with 0 (), 1, 5, or 10 mM SAHA for
48 hr (fold change in HR23B levels relative to
0 was 6, 5.5, and 4, respectively). PCNA was
used as a loading control. The example shown is
representative of three different experiments.
(B) HR23B protein levels and localization in SAHA-
treated cells. Immunostaining shows the level of
HR23B in U2OS cells before and after treatment
with 5 mM SAHA for 48 hr. Nuclei were located by
comparison to DAPI staining. Scale bars = 10 mm.
(C) HR23B protein levels in U2OS cells treatedwith
different HDAC inhibitors. Immunoblots show in-
creased protein levels of HR23B after treatment
for 48 hr with trichostatin A (TSA) (1 mM), SAHA
(5 mM), PXD101 (1 mM), and valproic acid (VPA)
(10 mM), with actin as a loading control (fold
change in HR23B levels relative to mock was 7,
5.2, 6.5, and 6.5, respectively).
(D) HR23B is not regulated at the RNA level upon
HDAC inhibition. RT-PCR shows levels of HR23B
RNA after treatment of U2OS cells for 48 hr with
TSA, SAHA, PXD101, or VPA at the concentra-
tions described in (C) for 48 hr, with 18S rRNA
as a loading control (fold change in HR23B RNA
relative to 18S rRNA was 0.98, 0.99, 1.2, and 1.4,
respectively).
(E) HR23B is acetylated. Immunoprecipitation
from U2OS cell extracts with anti-HR23B or
GAL4 antibody (as a nonspecific control) from
cells either untreated or treated with 5 mM SAHA
for 48 hr is shown. Immunoblotting was subse-
quently performed with an antibody against pan-
acetyl-lysine. Input levels of HR23B and PCNA
as a loading control are also shown.
(F) Quantification of relative levels presented in (E).
The level of acetylated or total HR23B in the im-
munoprecipitate from untreated cells (; lane 1
in [E]) was given an arbitrary value of 1 and used
to calculate the fold increase in SAHA-treated
cells (+).
(G) HR23B protein levels are not regulated by
DNA-damaging agents. Immunoblots show
HR23B protein levels after treatment of U2OS
cells for 48 hr with SAHA (5 mM), MG132 (0.5 mM),
combination of SAHA (5 mM) and MG132
(0.5 mM), ultraviolet (UV) light (50 J), doxorubicin
(10 mM), etoposide (20 mM), or bleomycin (1 mg/ml).
PCNA was used as a loading control.
(H) Quantification of relative protein levels in (G)
with respect to PCNA.
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treated cells. SinceGFPu is degraded via the proteasome (Bence
et al., 2001) (Figure 3D), these results support the idea that re-
duced levels of HR23B reinstate proteasome activity in HDAC
inhibitor-treated cells.
The proteasome is becoming increasingly recognized as a via-
ble cancer target, and a variety of small-molecule drugs that
interfere with proteasome activity are either in development
or already approved for clinical use (Nalepa et al., 2006). In
a fashion similar to HDAC inhibitors, proteasome inhibitors
Figure 3. Proteasome Activity in HDAC
Inhibitor-Treated Cells
(A) Loss of XPC does not affect cell sensitivity to
SAHA. Graph shows the percentage of XP4PA
(:), M2C5 (-), and U2OS (A) cells in sub-G1
as determined by FACS after treatment with in-
creasing concentrations of SAHA (0, 1, 2, 5, and
10 mM) for 48 hr. The values obtained in the differ-
ent cell lines were not significantly different at each
concentration of SAHA. n = 4; error bars = SEM.
(Ba–Bd) Loss of XPC does not impact the regula-
tion of HR23B levels after SAHA treatment. Immu-
noblots show expression levels of XPC in the
indicated cell types (Ba) and levels of HR23B after
treatment with increasing concentrations of SAHA
for 48 hr in U2OS (Bb), XP4PA (Bc), andM2C5 (Bd)
cells, with PCNA as a loading control.
(Ca and Cb) HDAC inhibitor treatment and binding
of HR23B to the 20S proteasome.
(Ca) Immunoprecipitation of U2OS cells with anti-
HR23B or control anti-GAL4 antibody (NS) either
untreated () or treated (+) with SAHA (5 mM) for
48 hr and subsequently immunoblotted with anti-
HR23B or 20S proteasome antibody. Input levels
are shown together with PCNA as a loading con-
trol (lanes 5 and 6). There was a 4-fold increase
in the level of HR23B associated with the 20S pro-
teasome in SAHA-treated cells.
(Cb) U2OS cells were treated as described above,
and extracts were immunoprecipitated with anti-
20S core a6 subunit or control antibody and
subsequently immunoblotted with anti-HR23B or
anti-20S core a6 subunit antibody. Input levels
are shown together with actin as a loading control
(lanes 1 and 2). There was a 4-fold increase in
the level of HR23B associated with the 20S
proteasome.
(D) GFP-u1 HEK293 cells express an unstable
GFP, GFPu, after treatment with bortezomib. Im-
munoblots show expression of GFPu protein,
with PCNA as a loading control. GFP-u1 cells
were either untreated () or treatedwith increasing
concentrations (in nM) of bortezomib for 48 hr as
indicated. Cells were also treated with the prote-
ase inhibitors aprotinin (A), leupeptin (L), or pep-
statin (P) as a control.
(E) GFP-u1 cells express GFPu after treatment with
HDAC inhibitors. Immunoblots show expression of
GFPu, with PCNA as a loading control. GFP-u1
cells were untreated () or treated with aprotinin
(A, 1 mg/ml), TSA, SAHA, or PXD101 for 48 hr as indicated. The fold change relative to mock for TSA, SAHA, and PXD101 was 33, 24, 20, 22, 23, and 34
(lanes 3–8, respectively).
(F) RT-PCR showing levels of GFP RNA after treatment of GFP-u1 cells for 48 hr with bortezomib, MG132, SAHA, or TSA as indicated; M indicates mock treat-
ment. 18S rRNA levels were used as a loading control. The fold change in GFP RNA relative to 18S rRNA is shown underneath; indicates the no-primer control.
(Ga) Purified proteasomes were incubated with vehicle (-), SAHA (,), PXD101 (d), or bortezomib (6) for 10 min prior to fluorogenic substrate addition. Cleaved
substrate representative of active proteasome was measured at 2 min intervals for 60 min. Data are presented in arbitrary fluorescent units (AFU).
(Gb) U2OS cells were treated with vehicle (A), SAHA (-), or bortezomib (:) and harvested at 4 hr, when HR23B levels had begun to change. Purified protea-
somes were then incubated with fluorogenic substrate. Cleaved substrate representative of active proteasome was measured at 2 min intervals for 18 min. n = 3;
error bars = SD.
(H) GFP-u1 cells were treated undermock conditions or with SAHA (30 mM) and either nontargeting control (NT; 100 nM) or HR23B siRNA (as indicated in nM), and
the levels of GFP, HR23B, and actin (as a loading control) were measured by immunoblotting at 48 hr.
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2006). Since HR23B is likely to be responsible for the altered pro-
teasome activity observed in HDAC inhibitor-treated cells, we
surmised that HR23B might also influence the sensitivity of cells
to proteasome inhibitors. Indeed, HR23B siRNA caused a dra-
matic reduction in the level of apoptosis induced by the protea-
some inhibitor MG132 in U2OS cells (Figures 4A–4C). Further-
more, HR23B was induced upon treating U2OS cells with the
proteasome inhibitor MG132 (Figure 2G; Figure 4C), reaching
levels similar to those seen in cells treated with HDAC inhibitors.
HR23B is therefore functionally important in mediating tumor cell
sensitivity to both HDAC and proteasome inhibitor drugs, sug-
gesting that HDAC and proteasome inhibitors act on overlapping
pathways.
HR23B Expression in Clinical CTCL Biopsies
Although it remains unclear which tumors undergo a favorable
clinical response to HDAC inhibitors, the hematological malig-
nancy cutaneous T cell lymphoma (CTCL) has to date been
found to be particularly sensitive to HDAC inhibitor-based thera-
pies (Duvic and Zhang, 2006; Mann et al., 2007). We therefore
evaluated HR23B levels in tumor cell lines derived from hemato-
logical malignancies and thereafter evaluated their sensitivity to
HDAC inhibitors. In a small panel of cell lines derived from CTCL
andmultiple myeloma (MM), HR23B levels correlated with sensi-
tivity to SAHA (Figure 4D; Figure S2F). Following on this, it was
of interest to examine HR23B in clinical biopsies taken from
patients suffering from CTCL. By immunohistochemistry in bi-
opsy-verified CTCL, including mycosis fungoides and its leuke-
Figure 4. HDAC Inhibitors, Proteasome
Inhibitors, and HR23B
(Aa–Af) HR23B depletion leads to rescue of HDAC
inhibitor- and proteasome inhibitor-mediated apo-
ptosis. FACS profiles depict the effect of treatment
of U2OS cells with either lamin (Aa, Ac, and Ae) or
HR23B (Ab, Ad, and Af) siRNA for 48 hr followed by
a subsequent 48 hr treatment with normal culture
medium or medium containing 5 mM SAHA (Ab
and Ad) or 0.5 mMMG132 (Ae and Af). Cell viability
is shown in Figure S2E.
(B) Quantitation of FACS profiles presented in (A).
(C) Immunoblot showing protein levels of HR23B,
lamin,andPCNAfor theexperimentdescribed in (A).
(D) Levels of HR23B in multiple myeloma (MM)
and cutaneous T cell lymphoma (CTCL) cell lines
and HDAC inhibitor sensitivity. Extracts from the
indicated cell lines were immunoblotted with anti-
HR23B as indicated, with PCNA as a loading con-
trol. The HDAC inhibitor IC50 of each cell line is indi-
cated below, and the effect of theHDAC inhibitor on
the cell-cycle profile is shown in Figure S2F.
mic variant Se´zary syndrome, HR23B
was expressed at high levels (Table 1).
The expression of HR23B was localized
to malignant CD3-positive T cells and
areas of tumor mass (Figure 5). Since
some CTCL biopsies expressed low
levels of HR23B (Table 1), HR23B expres-
sion is not a general feature of CTCL. Moreover, HR23B levels
were low in nonmalignant tissue in which activated T cells
were present (according to anti-CD3 staining), such as chronic
dermatitis (Table 1; Figure 6A), and thus HR23B expression is
not a marker of activated T cells. HR23B is therefore highly ex-
pressed in malignant T cells in CTCL in situ, which represents
a malignancy that is known to be sensitive to HDAC inhibitor-
based therapies.
DISCUSSION
The Proteasome and HDAC Inhibitors
HDACs were originally regarded as a family of enzymes that act
principally at the epigenetic level by regulating histone acetyla-
tion, and therefore HDAC inhibitors were believed to cause cell
killing through influencing epigenetic control (Marks and Jiang,
2005; Inche and La Thangue, 2006). However, a variety of non-
histone and non-chromatin-associated proteins have since
been found to be acetylated, such that acetylation is presently
regarded more as a pleiotropic level of posttranslational modifi-
cation than one that is specifically associated with epigenesis
(Chan and La Thangue, 2001; Bolden et al., 2006; Xu et al.,
2007). Our study bears on the mechanisms through which
HDAC inhibitors kill tumor cells. Numerous mechanisms have
been proposed to explain HDAC inhibitor-induced cell death,
such as upregulation of death receptors, effects on angiogene-
sis, and regulation of cell-cycle checkpoints (Minucci and Pel-
icci, 2006; Bolden et al., 2006; Xu et al., 2007). The results
presented here raise the possibility that aberrant proteasome
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Histology
Number CTCL Diagnosis
Neoplastic Cells
Positive for HR23B
Neoplastic Cells
Negative for HR23B Characteristics
1 mycosis fungoides + CD3+, CD4+
2 mycosis fungoides +
3 Se´zary syndrome + CD3+, CD8+
4 mycosis fungoides +
5 mycosis fungoides + concomitant lymphomatoid papulosis
6 mycosis fungoides +
7 mycosis fungoides + CD2+, CD3+, CD30+
8 mycosis fungoides + CD30+
9 mycosis fungoides + CD3+, CD30+
10 mycosis fungoides + CD2+, CD4+, CD5+, CD30+
11 cutaneous cytotoxic T cell lymphoma + CD8+
12 cutaneous anaplastic large cell lymphoma + CD30+
13 cutaneous lymphoproliferative disorder + CD30+
14 cutaneous lymphoproliferative disorder + CD4+, CD8+, CD30+
15 cutaneous lymphoproliferative disorder + CD30+
16 low-grade T cell lymphoma +
17 chronic dermatitis (+)
Diagnosis of disease is indicated. A biopsy taken from chronic dermatitis (histology number 17) showed a high infiltration of inflammatory nonmalignant
T cells, indicated as (+), that expressed low levels of HR23B (see Figure 6A).activity contributes to the killing process because HR23B, iden-
tified through a genome-wide loss-of-function screen for genes
that govern sensitivity to HDAC inhibitor-induced apoptosis, is
functionally important in mediating the effect of HDAC inhibitors.
Specifically, depleting HR23B reduced the sensitivity of tumor
cells to apoptosis resulting from HDAC inhibitors. While
HR23B functions in shuttling cargo proteins to the proteasome
as well as in NER (Sugasawa et al., 1997; Chen et al., 2001),
our evidence suggests that it is the proteasome shuttling activity
that is the important property in HDAC inhibitor-treated cells. It
is consistent with this idea that the association between HR23B
and the proteasome increased, and that proteasome activity
was compromised, in HDAC inhibitor-treated cells. Importantly,
the level of HR23B had a direct influence on protein turnover
mediated by the proteasome because depleting HR23B rein-
stated proteasome activity in HDAC inhibitor-treated cells. Pro-
teasome activity therefore appears to be regulated in HDAC in-
hibitor-treated cells through a process that involves HR23B
(Figure 6B). While these results do not exclude other mecha-
nisms and pathways contributing to HDAC inhibitor-induced
cell death (Richon, 2006; Bolden et al., 2006), they do strongly
implicate HR23B and the proteasome as components of a path-
way that is under aberrant control in cells treated with HDAC
inhibitors.
HDAC Inhibitors in the Clinical Setting
In addition to its effects in HDAC inhibitor-treated cells, HR23B
governs the susceptibility of tumor cells to drugs that act directly
on the proteasome. While this observation is of intrinsic interest,
it also lends support to the idea that HDAC inhibitors influence
proteasome activity, and furthermore that HDAC and protea-
some inhibitors induce apoptosis through overlapping mecha-nisms. The latter point is particularly relevant and could have im-
portance in the clinical setting, where combination therapies are
frequently employed to achieve maximum clinical effect. In
a therapy involving an HDAC inhibitor and proteasome inhibitor,
a delicate balance of drug dose and scheduling might be re-
quired to achieve the necessary level of proteasome inhibition
to mediate antitumor activity.
Although numerous ideas have been proposed (Duvic and
Zhang, 2006; Richon, 2006; Xu et al., 2007), the mechanism or
mechanisms through which HDAC inhibitors exert antitumor ac-
tivity in CTCL are not known. Consequently, it remains unclear
whether CTCL is the sole malignancy that is unusually sensitive
to HDAC inhibitors or alternatively represents one ofmanymalig-
nancies yet to be proven sensitive. As phase 2 proof-of-concept
clinical studies become available, it will become possible to eval-
uate this important question. However, clinical trials are often
lengthy, and equally importantly, it is a challenging exercise to
predict tumor response to the therapy under investigation with-
out an informative biomarker. It might be possible to accelerate
our knowledge of the clinical spectrum of responsive tumors if
biomarkers that act in a predictive fashion can be identified.
The expression of HR23B in tumors could offer such an opportu-
nity, and by correlating expression level with clinical response, it
should be possible to evaluate this idea.
In conclusion, we have used a genome-wide loss-of-function
screening approach to interrogate the mechanisms of HDAC in-
hibitor-induced cell death. Our study has unearthed a pathway,
involving proteasome activity and the proteasome-targeting ac-
tivity of HR23B, that is altered in HDAC inhibitor-treated cells.
The results point toward a level of control mediated via the pro-
teasome that contributes to the anticancer activity of HDAC
inhibitor-based therapies.Cancer Cell 15, 57–66, January 6, 2009 ª2009 Elsevier Inc. 63
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pRetroSuper shRNA Loss-of-Function Screen
Viral pools were produced by transfection of Phoenix packaging cells with the
pRetroSuper shRNA library (Berns et al., 2004) using calcium phosphate pre-
cipitation. U2OS cells expressing the murine ecotropic receptor (U2OSEcR)
were then infected with the viral pools. Cells were grown for 72 hr to allow
for shRNA expression and then plated overnight (40,000 cells per plate). Sub-
eroylanilide hydroxamic acid (SAHA; 2 mM) was then added to each plate.
SAHA-containing medium was replaced every 3 days for 25 days until the ap-
pearance of colonies on plates treated with SAHA and viral library. Colonies
Figure 5. Expression of HR23B in Cutaneous T Cell Lymphoma
In Situ
(A and B) Examples of tissue sections taken from CTCL biopsies showing he-
matoxylin and eosin staining (left), anti-CD3 immunostaining (middle), and anti-
HR23B immunostaining (right).
(A) Mycosis fungoides (histology number 7).
(B) Cutaneous cytotoxic T cell lymphoma (histology number 11). Insets show
increased magnifications taken from the corresponding images.
(Ca–Cd) Cutaneous lymphoproliferative disorder (histology number 13). Note
that the intensely stained malignant (CD3-positive) T cells in (Cb) correspond
with areas of HR23B staining in (Cc). (Cd) shows an increased magnification
of the tumor mass in (Cb). In (Aa)–(Ac), (Ba)–(Bc), and (Ca)–(Cc), each image
in the triplet represents a separate serial section from the biopsy.
Scale bars = 50 mm.64 Cancer Cell 15, 57–66, January 6, 2009 ª2009 Elsevier Inc.were then picked and expanded to allow isolation of total genomic DNA and
protein. Genomic DNA was isolated from surviving cells as described previ-
ously (Berns et al., 2004).
The complete shRNA library (Berns et al., 2004) was screened. From the pri-
mary screen, 132 colonies were isolated, and of these, about 17 grew in 2 mM
SAHA (Figure S1). The shRNA inserts were identified by PCR. Several colonies
contained multiple shRNA vectors and were deprioritized. Six colonies failed
to grow, or grew very slowly. HR23B (gene ID NM_002874) and the remaining
11 genes identified (gene IDs NM_002411, NM_002123, NM_002855, NM_
016186, NM_000521, NM_002300, NM_002309, NM_002310, NM_002372,
NM_016445, and NM_013352) are summarized in Figure S1.
Pathology Examination
CTCL diagnosis was verified by examination by three independent patholo-
gists. Paraffin-embedded formalin-fixed tissues from 15 CTCLs were sec-
tioned (5 mm) onto glass slides, cleared of paraffin in Citroclear, and rehydrated
through graded alcohol baths. After a rinse in water, sections were ‘‘pressure
cooked’’ for 2 min in 1 mM EDTA at pH 8 for heat-induced epitope retrieval.
Slides were incubated in 0.03% hydrogen peroxide for 5 min to inactivate en-
dogenous peroxidases, incubated with 0.1% Triton for 10 min to improve an-
tibody penetration, and treatedwith anti-HR23B or anti-CD3 followed by rabbit
anti-mouse HRP secondary antibody and then substrate (DAB; DAKO). Slides
were placed in hematoxylin (Sigma) for 1–2 s for nuclear counterstaining and
then mounted with coverslips using AquaTex (Merck). Sections were exam-
ined under a Zeiss Axioskop light microscope. Images were captured with Mi-
croPublisher 5.0 RTV, and imaging was performed with Adobe Photoshop 8.0.
Use of human tissues in this study was approved by the Oxfordshire Research
Ethics Committee (ref. no. CO2.216).
Proteasome Assay
The proteasome assay components were reconstituted and stored under con-
ditions described by BIOMOL International. Assay buffer was added to each
well as follows: 40 ml in blank (no proteasome), 30 ml in control (no inhibitor),
and 25 ml in inhibitor wells. 20S purified proteasome (10 ml) from human eryth-
rocytes was added to all wells except blanks. SAHA (5 mM), PXD101 (1 mM),
bortezomib (90 nM), and epoxomicin (0.5 mM) were added to all wells except
blanks and controls. Following 10 min incubation at room temperature, 10 ml
Suc-LLVY-AMC substrate, which measures chymotrypsin-like peptidase ac-
tivity, was added to all wells. The plate was read every 2 min for 1 hr using a
plate reader (360 nm excitation, 460 nm emission, gain = 58).
Assay for Proteasome Activity from HDAC Inhibitor-Treated Cells
U2OS cells were harvested after 4 hr of treatment with SAHA (5 mM), PXD101
(1 mM), bortezomib (90 nM), or vehicle control. Following a wash in 13 PBS,
cells were resuspended in 100 ml HEPES buffer (5 mM HEPES, 1 mM EDTA
[pH7.5]) and sonicated for 1 min. Samples were centrifuged for 10 min
(14,000 rpm at 4C) and the supernatant was removed, stored on ice, and
used immediately. Proteasome activity per sample was measured by adding
30 ml cell lysate to each well in triplicate. Assay buffer (40 ml) was added as
a blank. The fluorogenic substrate Suc-LLVY-AMC was added to all samples
and incubated for 10 min at room temperature. The plate was read every 2 min
for 1 hr on a plate reader (360 nm excitation, 460 nm emission, gain = 58).
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures and
three figures and can be found with this article online at http://www.
cancercell.org/supplemental/S1535-6108(08)00406-6.
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